Regeneron: Canaccord still a buyer, raises target price

(CercleFinance.com) - Canaccord reinstates its "buy" recommendation on the Regeneron share, having raised its corresponding target price from 630 dollars to 660 dollars, pointing to long-term data on Libtayo that "cements" its position in advanced squamous cell carcinoma.


"Going forward, we continue to expect strong growth from Dupixent, Libtayo, and EYLEA (in the diabetic indications)," the broker said, adding that it is "encouraged by the Sanofi agreement restructuring".

According to Canaccord, this restructuring could give the US pharma lab "wholly-owned products and increase its operating margins".


Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.